Mother nature's combinatorial libraries; their influence on the synthesis of drugs

Current Opinion in Drug Discovery and Development

Volumn 5, Issue 2, 2002, Pages 304-316

  Kingston, David G I ^a   Newman, David J ^a  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

Cell cycle inhibitor; Natural products; Privileged structures; Tubulin interactive agents

Indexed keywords

NATURAL PRODUCT;

ANALGESIA; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; COMBINATORIAL LIBRARY; DRUG SYNTHESIS; EVOLUTION; MARINE ENVIRONMENT; REVIEW; STEREOCHEMISTRY;

ANALGESICS; ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; BIOLOGICAL FACTORS; CELL CYCLE; GENE LIBRARY; HUMANS; PLANTS, MEDICINAL;

EID: 0036489886     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Proteomics: Defining protein function in the post genomics era
2. Natural products in drug discovery and development
3. The influence of natural products upon drug discovery
4. Why are secondary metabolites (natural products) biosynthesized?
5. Functionalized polymers - Emerging versatile tools for solution-phase chemistry and automated parallel synthesis
6. Promotion of microtubule assembly in vitro by taxol
7. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol
8. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action
9. Eleutherobin, a new cytotoxin that mimics paclitaxel (Taxol) by stabilizing microtubules
10. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents
11. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data
12. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia
13. Chemistry and biology of taxol
14. Medicinal chemistry of paclitaxel: Chemistry, structure-activity studies and solution conformations
15. Taxol, a molecule for all seasons
16. Recent advances in the medicinal chemistry of taxoids with novel β-amino acid side chains
17. Recent strategies in the development of taxane anticancer drugs
18. Synthesis and bioactivity of 2,4-diacyl analogs of paclitaxel
19. Design and synthesis of a taxoid library using radiofrequency encoded combinatorial chemistry
20. Synthesis and evaluation of paclitaxel C7 derivatives: Solution phase synthesis of combinatorial libraries
21. Phase I and pharmacoldnetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel
22. Preclinical antitumor activity of two novel taxanes
23. Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors
24. Epothilones A and B: Antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties
25. Antibiotics from gliding bacteria. 77. Epothilone A and B - Novel 16-membered macrolides with cytotoxic activity: Isolation, crystal structure, and conformation in solution
26. New natural epothilones from Sorangium celluosum. Strains So ce90/B2 and So ce90/D13: Isolation, structure elucidation, and SAR studies
27. Chemical biology of epothilones
28. A novel application of a Pd(0)-catalyzed nucelophilic substitution reaction to the regio- and stereoselective synthesis of lactam analogues of the epithilone natural products
29. On the interactivity of complex synthesis and tumor pharmacology in the drug discovery process: Total synthesis and comparative in vivo evaluations of the 15-aza epothilones
30. Isolation and characterization of the epothilone biosynthetic gene cluster from Sorangium cellulosum
31. Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel
32. Total syntheses of epothilones B and D
33. Total syntheses of epothilones A and B via a macrolactonization-based strategy
34. Synthesis of 16-desmethylepothilone B: Improved methodology for the rapid, highly selective and convergent construction of epothilone B and analogues
35. Syntheses of (-)-epothilone B
36. Total synthesis of epothilone B, epothilone D and cis and trans-9,10-dehydroepothilone D
37. Catalytic antibody route to the naturally occurring epothilones: Total synthesis of epothilones A-F
38. The biosynthetic gene cluster for the microtubule-stabilizing agents epothilones A and B from Sorangium cellulosum So ce90
39. The genetic manipulation of polyketide gene clusters as an approach to drug discovery
40. Development of a scalable epothilone D fermentation process using a heterologous host
41. Structure of curacin A, a novel antimitotic, antiproliferative and brine shrimp toxic natural product from the marine cyanobacterium Lyngbya majuscula
42. Biosynthesis of radiolabeled curacin A and its rapid and apparently irreversible binding to the colchicine site of tubulin
43. Total synthesis of the antimitotic marine natural product (+)-curacin A
44. Synthesis and biological evaluation of a focused mixture library of analogues of the antimitotic marine natural product curacin A
45. Cell cycle kinases and checkpoint kinases in cancer
46. 1001 Protein kinases redux - Towards 2000
47. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies
48. Protein kinase inhibitors: The tyrosine-specific protein kinases
49. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics
50. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy
51. Paullones, a series of cyclin-dependent kinase inhibitors: Synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity
52. Paullones
53. Paullones are potent inhibitors of glycogen synthase kinase-3β and cyclin-dependent kinase 5/p25
54. Cyclin-dependent Idnase inhibitors as potential anticancer, antineurodegenrative, antiviral and antiparasitic agents
55. Cytokinin-derived cyclin-dependent kinase inhibitors: Synthesis and cdc2 inhibitory activity of olomoucine and related compounds
56. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5
57. Biodiversity-based organic synthesis in the era of genomics and proteomics
58. Solution- and solid-phase strategies for the design, synthesis and screening of libraries based on natural product templates: A comprehensive survey
59. Studies on a new epidermal growth factor-receptor kinase inhibitor, erbstatin, produced by MH435-hF3
60. Kinetic studies of tyrosine kinase inhibition by erbstatin
61. Kinetics of inhibition by tyrphostins of the tyrosine kinase of the epidermal growth factor receptor and analysis by a new computer program
62. Tyrosine kinase inhibition: An approach to drug development
63. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells
64. Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: Structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins
65. Indirubin, the active constituent of a Chinese antileukemia medicine, inhibits cyclin-dependent kinases
66. Chemical constituents of a traditional Chinese medicine Qing Dai
67. Cyclin-dependent kinase and protein kinase C inhibitors: A novel class of antineoplastic agents in clinical development
68. Isolation of a novel tyrosine kinase inhibitor, lavendustin A from Streptomyces griseolavendus
69. A kinetic analysis of the inhibition of the epidermal growth factor receptor tyrosine kinase by lavendustin-A and its analogue
70. Design, synthesis and biological evaluation of a series of lavendustin A analogues that inhibit EGFR and Syk tyrosine kinases, as well as tubulin polymerization
71. Protein kinase delta
72. Protein kinase C: Structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions
73. Solid-phase synthesis and biological evaluation of teleocidin library - Discovery of a selective PKC-δ down regulator
74. Methods for drug discovery: Development of potent, selective, orally effective cholecystokinin antagonists
75. New 4-point pharmacophore method for molecular similarity and diversity applications: Overview of the method and applications, including a novel approach to the design of combinatorial libraries containing privileged substructures
76. Privileged structures - An update
77. Natural product-like combinatorial libraries based on privileged structures. 3. The 'Libraries from Libraries' principle for diversity enhancement of benzopyran libraries
78. Natural product-like combinatorial libraries based on privileged structures. 1. General principles and solid-phase synthesis of benzopyrans
79. Natural product-like combinatorial libraries based on privileged structures. 2. Construction of a 10,000-membered benzopyran library by directed split-and-pool chemistry using NanoKans and optical encoding
80. Polymer-supported selenium reagents for organic synthesis
81. Discovery of novel antibacterial agents active against methicillin-resistant Staphylococcus aureus from combinatorial benzopyran libraries
82. Virtual combinatorial libraries: Dynamic generation of molecular and supramolecular diversity by self-assembly
83. Dynamic combinatorial chemistry and virtual combinatorial libraries
84. Discovering high-affinity ligands for proteins: SAR by NMR
85. Combinatorial target-guided ligand assembly: Identification of potent subtype-selective c-Src inhibitors
86. Combinatorial library approach for the identification of synthetic receptors targeting vancomycin-resistant bacteria
87. Target-accelerated combinatorial synthesis and discovery of highly potent antibiotics effective against vancomycin-resistant bacteria
88. Solid and solution-phase synthesis of vancomycin and vancomycin analogues with activity against vancomycin-resistant bacteria
89. Synthesis and biological evaluation of vancomycin dimers with potent activity against vancomycin-resistant bacteria: Target-accelerated combinatorial synthesis
90. Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2-exo-2-(2′-substituted 5′-pyridinyl)-7-azabicyclo[2.2.1]heptanes. Epibatidine analogues
91. Syntheses and evaluation of halogenated cytisine derivatives and of bioisosteric thiocytisine as potent and selective nAChR ligands
92. Chemical genetics resulting from a passion for synthetic organic chemistry
93. Use of biomimetic-oriented synthesis to discover galanthamine-like molecules with biological properties beyond those of the natural product